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variable. CONCLUSIONS: Logistic regression using a generalized multinomial logit
link appears to provide a good propensity score fromwhich pseudo-randomization
into three groups can be performed in a retrospective sample.
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OBJECTIVES: Network meta-analysis of randomized controlled trials (RCTs) are
often based on one effect measure per study. However, many studies have data
available at multiple time points. Furthermore, not all studies might have mea-
sured the outcomes at the same time points. As an alternative to network meta-
analysis based on the results at one time point, a networkmeta-analysismethod is
presented that allows for the simultaneous analysis of outcomes at multiple time
points.METHODS: The development of outcomes over time of interventions com-
pared in a RCT are modeled with fractional polynomials, and the difference be-
tween the parameters of these polynomials within a trial are synthesized across
studies with a Bayesian network meta-analysis. RESULTS: The proposed models
are illustrated with an analysis of RCTs evaluating interventions for osteoarthritis
of the knee. Fixed and randomeffects first and second order fractional polynomials
were evaluated. CONCLUSIONS: Network meta-analysis with models where the
treatment effect is represented with several parameters using fractional polyno-
mials can be used to simultaneously analyze results at multiple follow-up times
that are not consistent across studies.
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Cole JC
Covance Market Access Services, Inc., San Diego, CA, USA
OBJECTIVES: The FDA’s final Guidance for industry on patient reported outcome
(PRO) use in support of labeling claims was issued in December, 2009. In their
Guidance, the FDA noted that a study’s endpoint model must consider the hierar-
chy of multiple endpoints, including how PROs used for a label claim fit into this
hierarchy. Whereas most studies implement a basic sequential gatekeeping pro-
cess to articulate their hierarchy, this may place some potential labels at risk.
Researchers should be knowledge of the various ways familywise error is influ-
enced and how best to control for it with an informed multiplicity plan as part of
their endpoint model. METHODS: Outcomes from previously published literature
were examined for the influence of various familywise error issues and related
multiplicity controls, including analytic issues, gatekeeping, and precision alpha
control (vs. Bonferroni or Hochberg). RESULTS: In a study with one clinical and
three PRO outcomes, A Bonferroni correction resulted in just one significant result.
A gatekeep between primary and secondary outcomes resulted in two significant
findings. Finally, when using either an adjustment for known-levels of correlation
to adjust alpha (Tukey’s test of statistical certainty) or using a repeated measures
ANOVA vs. change-score analysis, three of the outcomes were classified as
significant. CONCLUSIONS: Researchers should understand the implications of
theirmultiplicity control in order tomake informed decisions about their analyses,
organization of their endpointmodel, and ultimatelymake the best plans to ensure
their desired PRO-based label claims have the most accurate demonstration of
their statistical probability.
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OBJECTIVES: In Health Economics, the estimation of disease specific attributable
cost is of major importance. For this estimation, cost data of cases (patients with
the disease) and comparable controls (patients without the disease) are often uti-
lized. When individual level data are available, regression and GLM models, ad-
dressing issues such as skeweness and heteroscedasticity, can be applied. When
only aggregate level data (e.g. sample means and standard deviations per strata)
are available, thesemodelsmay not be appropriate.METHODS:Here,motivated by
real pressure ulcer cost data, we propose and study a Bayesian Gamma regression
mixed model that utilizes as stochastic nodes both sample means and inverse
coefficients of variation. We investigate its performance and goodness of fit (using
deviance) using various simulated data and compare it with two linear models,
assuming known and unknown cost variances per stratum. We also use the
method for estimating pressure ulcer attributable costs. RESULTS: In most cases,
the linear models give more accurate estimates of the attributable cost, with sig-
nificantly shorter computational time. The random effects adapt to the multipli-
cative nature of the data, posterior means between intercept and slope are posi-
tively correlated. CONCLUSIONS: When only aggregate data are available, the
simplest linear model seems to estimate the attributable costs sufficiently well.
The proposed Gamma model, despite being more theoretically justifiable, is of
questionable benefit. Further investigation is needed for refining the Gamma
model and selecting appropriate measures of model assessment and comparison.
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OBJECTIVES: It is a common practice to use a log link and assume a gamma distri-
bution when performing regressions of health care costs as an outcome on a set of
potential predictors. In many circumstances, this approach is reasonable and per-
forms well; however, do circumstances exist where these assumed model charac-
teristics are untenable? If so, do simple diagnostic procedures exist that can assess
the appropriateness of model assumptions for regressionmodels involving cost as
an outcome? METHODS: Application of residual analyses available in common
statistical software packages (e.g., SAS) afford practitioners the ability to graphi-
cally and analytically evaluatewhether the choice of a link is appropriate in a given
cost model regression scenario. These same tools can also assist with an assess-
ment of overall model fit. RESULTS: The author will juxtapose contrasting cases of
where the choice of a generalized linear model with a log link and an assumed
gamma distribution are defensible and where these assumptions are not met and
may lead to errors in subsequent inference. CONCLUSIONS:With the use of these
readily available diagnostic procedures found in common software packages it is
possible to easily evaluatewhether underlyingmodel assumptions are tenable and
if the choice of a simpler, more common approach may actually demonstrate
higher fidelity to its underlying model assumptions than the commonly used gen-
eralized linear model with a gamma distribution and a log link.
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OBJECTIVES: Increasingly, network meta-analysis (NMA) of published survival
data are based on parametric survival curves as opposed to reported hazard ratios
to avoid relying on the proportional hazards assumption, which may not be valid.
One advantage of a Bayesian approach to NMA is that the probability of being the
best treatment out of all those compared can be calculated. This directly supports
decision-making. However, in the context of survival analysis multiple options are
available.METHODS: Based on a case study in oncology, the probability that each
treatment is best in terms of overall survival was calculated and presented based
on the following underlying RESULTS: 1) the hazard over time, 2) the cumulative
hazard over time, 3) the survival proportions over time, 4) the expected survival
over time, 5) the expected survival at maximum follow-up, 6) expected survival
when all patients have died, and 7) median survival. RESULTS: Since the NMA of
survival curves results in changing hazard and survival estimates over time for the
compared interventions, calculations of the probability that a certain treatment is
best varies with the different alternatives. With methods 1-4 the probability that a
certain treatment is best will vary as a function of follow-up, which provides rele-
vant information. With methods 5-7 only one probability of being the best is ob-
tained for each treatment, which is easier to understand. Method 1 does not di-
rectly relate to the survival proportion, whichmakes it not very intuitive. Method 7
discards a lot of information. CONCLUSIONS: Different approaches to present the
probability of being the most efficacious treatment for findings obtained with a
NMA of survival curves have pros and cons. The probability that a certain treat-
ment is best as a function of survival proportions over time, as well as expected
survival over time seem the most useful and intuitive.
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OBJECTIVES: As an alternative to network meta-analysis (NMA) of survival data
based on the single constant hazard ratio (HR), NMA with a multi-dimensional
treatment effectwere introduced recently.With thesemodels theHR ismodeled as
a function of time, and violations of the transitivity assumption are less likely. Bias
is still present, however, if there are systematic differences in effect modifiers
across comparisons. The objective of this paper is to extend multidimensional
NMA models for survival data with treatment-by-covariate interactions to adjust
for confounding bias.METHODS: By means of an example network of randomized
controlled trials evaluating different interventions for melanoma, three different
approaches for the analysis of overall survival (OS) are compared. 1) NMAassuming
a constant HR between treatment and control group for each study; 2) a two-
dimensional NMA model assuming survival outcomes are described by a Weibull
function; and 3) an extension of method 2 with treatment-by-covariate interac-
tions to adjust for systematic differences across studies. RESULTS: The models
with the two-dimensional treatment effect (approach 2 and 3) fit more closely to
the data than the model with the constant HR (approach 1). Adding treatment-by-
covariate interactions for the scale parameter of the two-dimensional NMAmodels
reduced inconsistency. CONCLUSIONS: Adding treatment-by-covariate interac-
tions to multi-dimensional NMA models for published survival curves is worth-
while to explain systematic differences across studies and reduce inconsistencies.
An additional advantage is that heterogeneity in survival data can be addressed.
A167V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 – A 2 5 6
